On 13 November 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its November 2026 meeting, including positive opinions for the following two biosimilars to Novo Nordisk’s NovoRapid® (insulin aspart):
- Garzulys®, for which the EU marketing authorisation applicant is SciencePharma Sp. z.o.o; and
- Donrafylix™, with the EU marketing authorisation applicant being Belgian pharmaceutical company, Kuraci.
Both biosimilars are indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
The positive CHMP opinion for Garzulys® follows FDA approval for the biosimilar in July 2026. Garzulys™ was developed by China-based Tonghua Dongbaou Pharmaceutical. The US Biologics License Application (BLA) is held by Emerge Biosciences and Meitheal Pharmaceuticals is the US regulatory agent with exclusive US commercialisation rights for Garzulys® under a 2023 licence agreement with Emerge.
Insulin aspart biosimilars approved in Europe include Sandoz’s Dazparda® (approved May 2026), Biocon’s Kirsty® (previously Kixelle®) (approved February 2021), and Insulin aspart Sanofi (approved June 2020).
